resistance is the most commonly used way that transposons are 
manipulated. 
Dr. McGarrity advised, since there could be no resolution of this 
issue, that Dr. Vidaver and other interested committee members 
correspond with Dr. Gartland's office to attempt to prepare a 
proposal for the next meeting of the RAC. 
IX. PROPOSED AMENDMENT OF APPENDIX C-IV TO INCLUDE BACILLUS 
LICHENIFORMIS (tab 1310/VI, 1312, 1330). 
Dr. Riley said the proposal had been made to add Bacillus 
lichenif ormis to Appendix C-IV of the NIH Guidelines because of 
similarity between it and Bacillus subtilis , which is presently 
on the list. She said she found no reason to believe that B . 
lichenif ormis is unsafe, and it could be left to local IBCs as to 
what containment should be for large-scale application, and that 
further they would have the option to deal with it at less than 
BL1-LS , in light of the previous discussions of the day. 
Dr. Roberts agreed. He said it would be inconsistent with the 
spirit of the NIH Guidelines not to include it because of its 
similarity to an organism already on the list. 
Dr. Gellert said he agreed in general, but he asked about the 
spore-forming potential of B. lichenif ormis . He also raised the 
issue that in the submission from Novo, it stated that if the 
proposed amendment was not agreed to, that each such non-exempt 
large-scale experiment would require special RAC review, and he 
questioned whether this would be the case. 
Dr. McGarrity said he believed that would depend on the fate of 
the amendments voted at today's meeting, but that in the worst 
possible case they would indeed have to come in with each 
individual application. 
Dr. Gellert added that the proposal is not unique to B . 
lichenif ormis , and this may set a precedent for other strains 
similar to B. subtilis . 
Dr. Fordham said as far as the organism being asporogenic, they 
assumed it would have to meet the criteria of having equal 
frequency of reversion with B. subtilis . Dr. Gellert asked that 
something denoting this be added to the language of the proposal. 
Dr. Riley then moved to approve the following: 
"In Appendix C-IV, add Bacillus lichenif ormis to the 
title and to the first sentence such that it would 
read: 
[164] 
Recombinant DNA Research, Volume 13 
